Dr Andy Pearlman, President CEO and Founder of Medgenics (AMEX:MDGN LON:MEDG), tells Proactiveinvestors that a number of things have come together: first validation of the clinical trial of EPODURE for the treatment of Sustained Anemia in Dialysis Patients, having been pushed by the US Food & Drug Administration straight into Phase II trials for its"biopump", it shows that the technology is safe and has "tremendous clinical benefit", second is the approval in Israel for a similar trial and then the attainment for a trial for MDGN's hepatitis biopump treatment. Andy also says that the appointment of Dr Sol Barer as Chairman of the board is excellent news. He says one cannot imagine a more "accomplished, famous and sought after leader in the biotechnology world" having started Celgene and building it up into a $25bln company.
About this content
About
About the publisher
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists.
Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth.
We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors.
The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies.
Use of technology
Proactive has always been a forward looking and enthusiastic technology adopter.
Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows.
Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.
No investment advice
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter. You understand...
FOR OUR FULL DISCLAIMER CLICK HEREMedgenics CEO says a number of factors set the company at beneficial "tipping point"
Published: 08:34 06 Jul 2012 BST